Molecular Prognostic Markers of Prostate Cancer: An Immunohistochemical Study on TMA Blocks from 428 Radical Prostatectomy Specimens
Woon Yong Jung, Jae Y Ro, Yong Mee Cho. University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Cornell University, The Methodist Hospital, Houston, TX
Background: Prostate cancer is a heterogeneous disease, ranging from clinically insignificant tumor to a rapidly fatal malignancy. Recent studies suggested molecular classification using zinc-alpha-2-glycoprotein (AZGP1), hCAP-D3, and mucin 1 (MUC1) and expressions of ERG gene fusion product and vimentin as prognostic markers of prostate cancer.
Design: A tissue microarray construct of prostate cancer tissues was generated from 428 cases that underwent radical prostatectomy from 1996 to 2006. Expressions of AZGP1, hCAP-D3, MUC1, ERG and vimentin as well as Ki-67 as a proliferation marker were assessed immunohistochemically and correlated with their clinical significance.
Results: Low expression of AZGP1 was associated with biochemical recurrence, clinical progression and increased risk of cancer-specific death. Whereas high expression of hCAP-D3, MUC1, and ERG was correlated with increased biochemical recurrence, and high expression of vimentin was correlated with clinical progression. Ki-67 expression was not informative due to low expression in most of cases. In multivariate analysis, only low expression of AZGP1 was a strong negative predictor of overall survival independent of Gleason score, pathologic tumor stage and resection margin involvement.
Conclusions: AZGP1, hCAP-D3, MUC1, ERG, and vimentin can be useful immunohistochemical prognostic markers. Validation of our results awaits further studies.
Category: Genitourinary (including renal tumors)
Tuesday, March 20, 2012 1:00 PM
Poster Session IV # 105, Tuesday Afternoon